Remoxy's "Complete Response" Letter Has No Clear Culprit But Many Suspects
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's abuse-deterrent, extended-release form of pain drug oxycodone faces legal, regulatory and manufacturing challenges.